A new covid-19 vaccine made by Novavax will now be assessed by UK regulators after showing 89% efficacy in major trials in Britain.
The UK's ordered 60 million doses of the jab which will be manufactured in northern England.
Trials showed it to be effective against the so-called 'UK variant' which has been spreading quickly in Britain and a number of other countries.
It was less effective against the variant discovered in South Africa.
But Dr Gregory Glenn, president of research and development at Novavax, says the results are encouraging nonetheless.
IN: "We know....
OUT: ...strains."
DUR: 16 seconds